Dihydroergocornini esilas,Dihydroergotoxini mesilas,Dihydroergocryptini esilas,Dihydroergocristini esilas - search results

United States - English - NLM (National Library of Medicine)

ergoloid mesylates- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydr

carilion materials management - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon

United States - English - NLM (National Library of Medicine)

ergoloid mesylates- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydr

sun pharmaceutical industries, inc. - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon

United States - English - NLM (National Library of Medicine)

ergoloid mesylates tablets usp oral 1mg

frontida biopharm, inc. - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) -